In June 2021, aducanumab, the first drug to target the cause of Alzheimer's disease, was approved in the US, making headlines worldwide. We look at the results of clinical trials involving over 3,000 participants from 20 countries, differences between the drug and conventional treatments, and the drug's limitations. We also focus on a preceding condition called mild cognitive impairment, or MCI. Japanese researchers developed a way to reverse cognitive decline in those with MCI, and a test to see whether someone is developing it.
A Japanese specialist involved in clinical trials for aducanumab talks about the drug's effects and limitations
This man was diagnosed with MCI and is taking steps to improve his cognitive function
This researcher developed a test that reveals how close someone is to developing MCI
We introduce muscle-training methods that use pain to stimulate the brain